32 recruiting, 16 active not recruiting, 8 not yet recruiting, 2 terminated. 47 Phase 2, 16 Phase 1, 6 Phase 3.
Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi) epcoritamab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 24 | 2026-11-11 | 2026-11-06 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas Glofitamab, Epcoritamab, Polatuzumab Vedotin - Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | Phase 2 | Recruiting | National Research Center for Hematology, Russia | 40 | 2026-09-01 | 2026-10-20 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation Epcoritamab, Pirtobrutinib, Cyclophosphamide - Richter Transformation | Phase 2 | Recruiting | German CLL Study Group | 116 | 2026-06-18 | 2026-11-05 |
| External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL Epcoritamab, Glofitamab, External Beam Radiation Therapy - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2026-06-01 | 2026-06-04 |
| Low Dose Epcoritamab Plus GemOx in R/R DLBCL Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin - Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2026-03-17 | 2026-04-01 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2026-01-07 | 2026-03-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab Epcoritamab - Primary CNS Lymphoma (PCNSL) | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 60 | 2025-09-22 | 2026-06-15 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2025-08-13 | 2026-07-14 |
Showing 20 of 62. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (26) · Lymphoma, Follicular (13) · Lymphoma, Non-Hodgkin (12) · Lymphoma (11) · Recurrence (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Neoplasms (8) · Lymphoma, B-Cell (6) · Lymphoma, B-Cell, Marginal Zone (6) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Waldenstrom Macroglobulinemia (2) · Cytokine Release Syndrome (1) · Leukemia (1) · Leukemia, B-Cell (1)
Genmab (17) · City of Hope Medical Center (4) · The Lymphoma Academic Research Organisation (3) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Reid Merryman, MD (2) · AIDS Malignancy Consortium (1) · AbbVie (1) · Abramson Cancer Center at Penn Medicine (1) · Academic and Community Cancer Research United (1) · Australasian Leukaemia and Lymphoma Group (1) · Beth Israel Deaconess Medical Center (1) · Bristol-Myers Squibb (1) · Carrie Ho, MD (1)
United States (45) · France (15) · Australia (13) · Spain (13) · Belgium (12) · Netherlands (12) · Denmark (11) · Germany (11) · Italy (10) · Japan (10) · South Korea (10) · United Kingdom (10) · Czechia (9) · China (8) · Poland (8)
Dai Chihara, MD (2) · Reid Merryman, MD (2) · Swetha Kambhampati (2) · Adrian U Wiestner, M.D. (1) · Alexey V Danilov (1) · Ariela Noy (1) · Carrie Ho, MD (1) · Catherine C Coombs, MD (1) · Christian Grommes, MD (1) · Elena Parovichnikova, MD, DSc (1) · Elise Chong, MD (1)
PMID 42411504, PMID 42541678, PMID 17431547, PMID 20209410, PMID 23873804, PMID 30698644, PMID 34508654, PMID 35834762, PMID 36548927, PMID 38151388, PMID 38528445, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40319227, PMID 40472301, PMID 40550489, PMID 40632620, PMID 40920572, PMID 41371238, PMID 41380698, PMID 41670385, PMID 41784015, PMID 42285113, PMID 42431612, PMID 42622258, PMID 42660129
2023 (10), P30CA033572 (4), 2017 (1), 2019 (1), 2025 (1), P30CA015083 (1), P30CA060553 (1), P30CA093373 (1), R01CA308586 (1), UM1CA121947 (1)